Th Unger

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi ["Hypertension 2008"]
    Thomas Unger

    MMW Fortschr Med 150:26. 2008
  2. ncbi Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro
    Karen Tiede
    Institute of Pharmacology, Christian-Albrechts-University, Kiel, Germany
    Cardiovasc Res 60:538-46. 2003
  3. ncbi Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches
    Thomas Unger
    Center for Cardiovascular Research, Charite University Medicine, Hessische Str 3 4, Berlin 10115, Germany
    Eur Heart J 32:2739-47. 2011
  4. ncbi Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients
    Ulrich Kintscher
    Center for Cardiovascular Research, Institute of Pharmacology, Charite, Berlin, Germany
    Cardiovasc Diabetol 6:12. 2007
  5. ncbi PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice
    Anna Foryst-Ludwig
    Center for Cardiovascular Research, Institute of Pharmacology Charité Universitätsmedizin Berlin, Germany
    Cardiovasc Diabetol 9:64. 2010
  6. ncbi Blood pressure lowering and renin-angiotensin system blockade
    Thomas Unger
    Institute of Pharmacology and Toxicology, , Humboldt University at Berlin, Germany
    J Hypertens Suppl 21:S3-7. 2003
  7. ncbi Telmisartan: from lowering blood pressure to end-organ protection
    Thomas Unger
    Charite University Medicine Berlin, Center for Cardiovascular Research CCR Institute of Pharmacology and Toxicology Hessische Strasse 3 4, 10115 Berlin, Germany
    Future Cardiol 1:7-15. 2005
  8. ncbi Lessons from ALLHAT. Are low budget diuretics first line therapy in hypertension?
    T Unger
    Center for Cardiovascular Research Institut für Pharmakologie und Toxikologie, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, 10117 Berlin, Germany
    Z Kardiol 93:349-56. 2004
  9. ncbi The role of the renin-angiotensin-aldosterone system in heart failure
    Thomas Unger
    Centre for Cardiovascular Research, Charite University, Berlin, 10115, Germany
    J Renin Angiotensin Aldosterone Syst 5:S7-10. 2004
  10. ncbi Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein
    Christoph J Wruck
    Institute of Pharmacology, University Hospital Schleswig Holstein, Campus Kiel, Germany
    Arterioscler Thromb Vasc Biol 25:57-64. 2005

Detail Information

Publications89

  1. ncbi ["Hypertension 2008"]
    Thomas Unger

    MMW Fortschr Med 150:26. 2008
  2. ncbi Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro
    Karen Tiede
    Institute of Pharmacology, Christian-Albrechts-University, Kiel, Germany
    Cardiovasc Res 60:538-46. 2003
    ..CONCLUSION: The results indicate that in cardiac fibroblasts AngII via the AT(1)-receptor causes autocrine release of TGFbeta1, which in turn induces biglycan expression and secretion...
  3. ncbi Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches
    Thomas Unger
    Center for Cardiovascular Research, Charite University Medicine, Hessische Str 3 4, Berlin 10115, Germany
    Eur Heart J 32:2739-47. 2011
    ..It remains an exciting question which approach will confer the best blood pressure control and risk reduction in this tricky disease...
  4. ncbi Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients
    Ulrich Kintscher
    Center for Cardiovascular Research, Institute of Pharmacology, Charite, Berlin, Germany
    Cardiovasc Diabetol 6:12. 2007
    ..Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care...
  5. ncbi PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice
    Anna Foryst-Ludwig
    Center for Cardiovascular Research, Institute of Pharmacology Charité Universitätsmedizin Berlin, Germany
    Cardiovasc Diabetol 9:64. 2010
    ....
  6. ncbi Blood pressure lowering and renin-angiotensin system blockade
    Thomas Unger
    Institute of Pharmacology and Toxicology, , Humboldt University at Berlin, Germany
    J Hypertens Suppl 21:S3-7. 2003
    ....
  7. ncbi Telmisartan: from lowering blood pressure to end-organ protection
    Thomas Unger
    Charite University Medicine Berlin, Center for Cardiovascular Research CCR Institute of Pharmacology and Toxicology Hessische Strasse 3 4, 10115 Berlin, Germany
    Future Cardiol 1:7-15. 2005
    ..Due to its long duration of action, it compares favorably with other angiotensin receptor blockers. Latest data from clinical trials and newest research regarding telmisartan will be reviewed in this article...
  8. ncbi Lessons from ALLHAT. Are low budget diuretics first line therapy in hypertension?
    T Unger
    Center for Cardiovascular Research Institut für Pharmakologie und Toxikologie, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, 10117 Berlin, Germany
    Z Kardiol 93:349-56. 2004
    ..In this role they could only do good and not cause any damage...
  9. ncbi The role of the renin-angiotensin-aldosterone system in heart failure
    Thomas Unger
    Centre for Cardiovascular Research, Charite University, Berlin, 10115, Germany
    J Renin Angiotensin Aldosterone Syst 5:S7-10. 2004
    ..The importance of the RAAS in heart failure is shown by the survival benefit conferred by treatment with ACE inhibitors...
  10. ncbi Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein
    Christoph J Wruck
    Institute of Pharmacology, University Hospital Schleswig Holstein, Campus Kiel, Germany
    Arterioscler Thromb Vasc Biol 25:57-64. 2005
    ..Little is known concerning the regulation of G protein-coupled receptor transport from the endoplasmic reticulum to the cell surface...
  11. ncbi The role of olmesartan medoxomil in the management of hypertension
    Thomas Unger
    Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, Charite University Medicine Berlin, Berlin, Germany
    Drugs 64:2731-9. 2004
    ....
  12. ncbi Targeting cardiovascular protection: the concept of dual renin-angiotensin system control
    Thomas Unger
    Centre for Cardiovascular Research CCR Institute of Pharmacology, Charite Universitatsmedizin, Berlin, Germany
    Medscape J Med 10:S4. 2008
    ....
  13. ncbi Rationale for double renin-angiotensin-aldosterone system blockade
    Thomas Unger
    Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, Berlin, Germany
    Am J Cardiol 100:25J-31J. 2007
    ..The benefits of this approach with telmisartan are being investigated in clinical trials, such as the Ongoing Telmisartan Alone in Combination with Ramipril Global Endpoint Trial (ONTARGET)...
  14. ncbi [Laudatio. On the presentation of the 2005 Robert Koch Award to the drug tiotropium bromide (spiriva)]
    Thomas Unger
    Center for Cardiovascular Research, ,
    Med Klin (Munich) 100:17-8. 2005
  15. ncbi [Innovation or pseudo-innovation: that is the question]
    Thomas Unger
    , , Berlin
    Med Klin (Munich) 101:257-62. 2006
  16. ncbi Blood pressure lowering and renin-angiotensin system blockade
    Thomas Unger
    Institute of Pharmacology and Toxicology, Charite Hospital, Humboldt University at Berlin, Germany
    J Hypertens Suppl 21:S3-7. 2003
    ....
  17. ncbi [New options in the drug treatment of hypertension: claim and reality]
    Th Unger
    , , Germany
    Dtsch Med Wochenschr 127:2404-6. 2002
  18. ncbi Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications
    T Unger
    Institute of Pharmacology and Toxicology, Charit Hospital, Humboldt University, Berlin, 10117, Germany
    J Renin Angiotensin Aldosterone Syst 2:S4-7. 2001
    ....
  19. ncbi The ongoing telmisartan alone and in combination with ramipril global endpoint trial program
    Thomas Unger
    Institute of Pharmacology and Toxicology, Charite Hospital, Humboldt University at Berlin, Berlin, Germany
    Am J Cardiol 91:28G-34G. 2003
    ....
  20. ncbi [ACE inhibitor or AT1 antagonist. Is there a differential therapy?]
    Th Unger
    Institut fur Pharmakologie und Toxikologie, Universitätsklinikum Charité der Humboldt Universität, Berlin
    MMW Fortschr Med 144:36-8. 2002
    ..The LIFE study has shown that an AT1 antagonist is superior to an established beta blocker in hypertensives with an increased risk (left-ventricular hypertrophy), in particular when diabetes mellitus is impending or already present...
  21. ncbi The role of the renin-angiotensin system in the development of cardiovascular disease
    Thomas Unger
    Institute of Pharmacology and Toxicology, Charite Hospital, Humboldt University at Berlin, Berlin, Germany
    Am J Cardiol 89:3A-9A; discussion 10A. 2002
    ....
  22. ncbi Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity
    Michael Schupp
    Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, Charité Campus Mitte Charité Universitätsmedizin Berlin, Hessische Str, 3 4 10115 Berlin, Germany
    Diabetes 54:3442-52. 2005
    ..This may provide a new therapeutic option for better cardiovascular risk management in metabolic diseases and may initiate the development of new classes of drugs combining potent antihypertensive and antidiabetic actions...
  23. ncbi Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity
    Michael Schupp
    Center for Cardiovascular Research, , , , Berlin, Germany
    Circulation 109:2054-7. 2004
    ..The activation of PPARgamma demonstrates new pleiotropic actions of certain ARBs, providing a potential mechanism for their insulin-sensitizing/antidiabetic effects...
  24. ncbi Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design
    Matthias G Friedrich
    HELIOS Klinikum Berlin, Humboldt Univeritat Berlin, Berlin, 13125, Germany
    J Renin Angiotensin Aldosterone Syst 4:234-43. 2003
    ..A separate study was performed prior to the main trial to define the normal range of MRI data in an age-matched population...
  25. ncbi Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation
    Kai Kappert
    Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, Berlin, Germany
    Hypertension 54:738-43. 2009
    ..Our data show that sufficient serum levels of EXP3179 are present under losartan treatment. PPARgamma activation by AT1R-blockers may translate into synergistic beneficial actions in monocytes...
  26. ncbi Effect of angiotensin AT2 receptor stimulation on vascular cyclic GMP production in normotensive Wistar Kyoto rats
    Christiane Pees
    Institute of Pharmacology, Christian-Albrechts University of Kiel, Hospitalstr. 4, 24105 Kiel, Germany
    Int J Biochem Cell Biol 35:963-72. 2003
    ..Aortic cyclic GMP levels were not significantly changed by either treatment. Our results demonstrate that the AT(2) receptor did not contribute to the cyclic GMP production in the vascular wall of normotensive WKY...
  27. ncbi PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin
    Ronald Clasen
    Center for Cardiovascular Research, , , , Berlin, Germany
    Hypertension 46:137-43. 2005
    ..ARB-induced adiponectin stimulation is likely to be mediated via PPARgamma activation involving a post-transcriptional mechanism...
  28. ncbi Are angiotensin receptor blockers neuroprotective?
    Christa Thone-Reineke
    Center for Cardiovascular Research CCR Institut für Pharmakologie und Toxikologie, Campus Charité Mitte Charité Universitätsmedizin Berlin, Hessische Strasse 3 4, 10115 Berlin, Germany
    Curr Hypertens Rep 6:257-66. 2004
    ..In doing so, we also attempt to shed some light on the mechanisms by which AT1 receptor blockers, which leave the AT2 receptor unopposed, might exert protective actions in brain ischemia...
  29. ncbi A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein
    Jan H Schefe
    Center for Cardiovascular Research Institute of Pharmacology, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, 10115 Berlin, Germany
    Circ Res 99:1355-66. 2006
    ..Our data demonstrate the existence of a novel signal transduction pathway involving the ligand renin, RER, and the transcription factor PLZF, which is of physiological and putative pathophysiological relevance...
  30. ncbi Low-dose lithium combined with captopril prevents stroke and improves survival in salt-loaded, stroke-prone spontaneously hypertensive rats
    Jihong Xu
    Institute of Pharmacology, University Hospital of Schleswig-Holstein, Campus Kiel, Germany
    J Hypertens 23:2277-85. 2005
    ..This effect was independent of a reduction in blood pressure...
  31. ncbi Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats
    Maxim Krikov
    Center for Cardiovascular Research CCR Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Hypertens 26:544-52. 2008
    ....
  32. ncbi Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites
    Michael Schupp
    Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, , Berlin, Germany
    Hypertension 47:586-9. 2006
    ..The present study characterizes the active losartan metabolite EXP3179 as a partial PPAR-gamma agonist. PPAR-gamma activation by EXP3179 may help us to understand the beneficial metabolic effects of losartan observed in clinical trials...
  33. ncbi Angiotensin in the kidney: a key to understanding hypertension?
    Ulrike Muscha Steckelings
    Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, 10115 Berlin, Germany
    Cell Metab 5:7-8. 2007
    ..However, in this experimental setting, hypertension-related left ventricular hypertrophy seemed to depend on blood pressure elevation rather than on the expression of AT1 receptors in the heart...
  34. ncbi Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain
    Kristin Schmerbach
    Center for Cardiovascular Research Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Brain Res 1208:225-33. 2008
    ..Therefore, we conclude that a direct synergistic neuroprotective action of parallel ARB and TZD treatment is unlikely...
  35. ncbi The endothelium and vascular inflammation in diabetes
    Martin M Hartge
    Center for Cardiovascular Research, Charite Universitaetsmedizin Berlin, Hessische Strasse 3 4, 10115 Berlin, Germany
    Diab Vasc Dis Res 4:84-8. 2007
    ..In the presence of insulin resistance, these processes are potentiated and they provide a basis for the macrovascular disease seen in diabetes...
  36. ncbi Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode
    Matthias Goebel
    Institute of Pharmacy, Freie Universitat Berlin, Berlin, Germany
    Bioorg Med Chem 18:5885-95. 2010
    ....
  37. ncbi Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats
    Peter Gohlke
    Institute of Pharmacology, Christian Albrechts University of Kiel, Germany
    J Hypertens 20:909-18. 2002
    ..In the present study, we investigated the ability of the peripherally administered angiotensin II type 1 (AT1) receptor antagonist, candesartan cilexetil, to block central effects of angiotensin II (Ang II) in conscious rats...
  38. ncbi [The ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial): primary antihypertensive agents - diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors]
    J Scholze
    Ambulante Spezialmedizin, Medizinische Poliklinik, , Germany
    Internist (Berl) 44:1193-5. 2003
  39. ncbi The AT2 receptor--a matter of love and hate
    U M Steckelings
    Center for Cardiovascular Research, Institut fur Pharmakologie und Toxikologie, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, 10115 Berlin, Germany
    Peptides 26:1401-9. 2005
    ..The present review summarizes the current knowledge of AT2 receptor distribution, signaling and function with an emphasis on growth/anti-growth, differentiation and the regeneration of neuronal tissue...
  40. ncbi Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan
    Markus Clemenz
    Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Hessische Str 3 4, 10115 Berlin, Germany
    Diabetes 57:1405-13. 2008
    ..Activation of the PPARalpha ligand binding domain (LBD) was investigated using transactivation assays...
  41. ncbi Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study
    Jurgen Scholze
    Department of Medicine, Outpatient Clinic, CCM, Charite Universitatsmedizin Berlin, Luisenstrasse 11 13, 10117 Berlin, Germany
    Circulation 115:1991-8. 2007
    ..To identify an optimal treatment regimen for obese hypertensive patients, we studied the interactions between a drug-based weight loss approach by sibutramine and different antihypertensive drug regimens...
  42. ncbi The angiotensin AT2 receptor in left ventricular hypertrophy
    U Muscha Steckelings
    Center for Cardiovascular Research, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, Berlin, Germany
    J Hypertens 28:S50-5. 2010
    ....
  43. ncbi Ethanol-induced downregulation of the angiotensin AT2 receptor in murine fibroblasts is mediated by PARP-1
    Mario Menk
    Department of Anesthesiology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum Campus Charité Mitte, 13353 Berlin, Germany
    Alcohol 44:495-506. 2010
    ..Variations in expression of the potentially tissue-protective AT2R might contribute to ethanol-mediated pathology...
  44. ncbi Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB
    Franziska Rompe
    Center for Cardiovascular Research, Charite Universitatsmedizin Berlin, Hessische Str 3 4, 10115 Berlin, Germany
    Hypertension 55:924-31. 2010
    ..These data suggest that pharmacological AT(2) receptor stimulation may be an orally applicable future therapeutic approach in pathological settings requiring the reduction of interleukin 6 or inhibition of nuclear factor kappaB...
  45. ncbi The past, present and future of angiotensin II type 2 receptor stimulation
    U Muscha Steckelings
    Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Germany
    J Renin Angiotensin Aldosterone Syst 11:67-73. 2010
    ..Moreover, it provides an overview of the first results obtained by direct AT(2) receptor stimulation with Compound 21, comprising effects on alkaline secretion, neurite outgrowth, blood pressure and post-infarct cardiac function...
  46. ncbi The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets
    Ulrike Muscha Steckelings
    Center for Cardiovascular Research CCR, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Fundam Clin Pharmacol 23:693-703. 2009
    ..The present article reviews the emerging knowledge about cardiovascular and non-cardiovascular effects of the RAS with an emphasis on the mechanisms of RAS involvement and pharmacological RAS inhibition in diabetic end organ damage...
  47. ncbi Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension
    Ulrich Kintscher
    Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Hessische Str 3 4, 10115 Berlin, Germany
    Diabetes Res Clin Pract 89:209-15. 2010
    ..The present study aimed to explore the impact of the angiotensin type 1 receptor blocker valsartan (VAL) on inflammatory-/lipid-/glucose parameters in hypertensive diabetic patients with and without coronary artery disease (CAD)...
  48. ncbi Adapter proteins and promoter regulation of the angiotensin AT2 receptor--implications for cardiac pathophysiology
    Heiko Funke-Kaiser
    Center for Cardiovascular Research CCR Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Renin Angiotensin Aldosterone Syst 11:7-17. 2010
    ....
  49. ncbi Transition from atherosclerosis to aortic aneurysm in humans coincides with an increased expression of RAS components
    Elena Kaschina
    Center for Cardiovascular Research Institute of Pharmacology, Charite Universitatsmedizin Berlin, Germany
    Atherosclerosis 205:396-403. 2009
    ..Taken together, our data suggest that in humans, RAS activation is not just a key-player in the pathogenesis of atherosclerosis, but that a further increasing activation may be involved in the transition from atherosclerosis to AAA...
  50. ncbi Novel therapeutic targets for hypertension
    Ludovit Paulis
    Center for Cardiovascular Research, Charite Universitatsmedizin, Hessische Strasse 3 4, 10115 Berlin, Germany
    Nat Rev Cardiol 7:431-41. 2010
    ..All of these strategies are exciting prospects, but which of them will prove valuable in clinical setting remains to be discovered...
  51. ncbi Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation
    Elena Kaschina
    Center for Cardiovascular Research CCR Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Hypertens 26:2361-73. 2008
    ..We investigated the effects of treatment with the angiotensin II type 1 receptor antagonist, telmisartan, on abdominal aortic aneurysm formation in normotensive rats...
  52. ncbi Inhibiting angiotensin type 1 receptors as a target for diabetes
    Ulrich Kintscher
    Charite Universitatsmedizin Berlin, Institute of Pharmacology, Center for Cardiovascular Research, Hessische Street, 3 4, 10115 Berlin, Germany
    Expert Opin Ther Targets 12:1257-63. 2008
    ..The mechanisms of the insulin-sensitizing/anti-diabetic effect are not fully understood, and may involve AT1 receptor-dependent pathways and 'pleiotropic' actions of ARBs including activation of insulin-sensitising PPARgamma...
  53. ncbi Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren
    Jan H Schefe
    Center for Cardiovascular Research CCR Institute of Pharmacology, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, Berlin, Germany
    J Hypertens 26:1787-94. 2008
    ..The effects of prorenin and of renin inhibitors on the signal transduction cascade of the (pro)renin receptor are currently unknown...
  54. ncbi Pharmacoeconomics and quality of life analysis of telmisartan in hypertension treatment
    Kristin Schmerbach
    Center for Cardiovascular Research CCR Institute of Pharmacology, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, 10115 Berlin, Germany
    Expert Rev Pharmacoecon Outcomes Res 7:435-44. 2007
    ..This article provides the most recent data of the pharmacoeconomic position of telmisartan and its treatment effects on quality of life...
  55. ncbi Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan
    Matthias Goebel
    Universitatsmedizin Berlin, Center for Cardiovascular Research CCR Institut für Pharmakologie und Toxikologie, Charite Campus Mitte, Charité Hessische Str 3 4 10115 Berlin, Germany
    Expert Rev Cardiovasc Ther 4:615-29. 2006
    ..The most recent data from clinical trials and latest research regarding telmisartan will be reviewed in this article...
  56. ncbi High prevalence and poor control of hypertension in primary care: cross-sectional study
    Arya M Sharma
    Franz Volhard Clinic Charité, Berlin, Germany
    J Hypertens 22:479-86. 2004
    ....
  57. ncbi Vasoactive peptides, their receptors and drug development
    Heike Kusserow
    Center for Cardiovascular Research Institute of Pharmacology and Toxicology, Campus Charite Mitte, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, D 10115 Berlin, Germany
    Basic Clin Pharmacol Toxicol 94:5-12. 2004
    ..In addition, the properties of indirectly acting drugs like angiotensin-converting enzyme inhibitors and--in analogy--endothelin-converting enzyme inhibitors will be presented...
  58. ncbi Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection
    Duska Dragun
    Department of Nephrology, Charite University Hospital, Berlin, Germany
    N Engl J Med 352:558-69. 2005
    ..Antibodies against HLA antigens cause refractory allograft rejection with vasculopathy in some, but not all, patients...
  59. ncbi Inhibiting angiotensin receptors in the brain: possible therapeutic implications
    Thomas Unger
    Charite Hospital, Humboldt University, Berlin, Germany
    Curr Med Res Opin 19:449-51. 2003
    ..Candesartan was the most effective angiotensin receptor blocker (ARB) in crossing the blood-brain barrier...
  60. ncbi HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patients
    U Muscha Steckelings
    Center for Cardiovascular Research Institute of Pharmacology and Toxicology, Charite, Berlin, Germany
    Blood Press 13:80-8. 2004
    ..These insights into the causes of unsatisfactory hypertension control may help to direct future educational programmes designed to improve hypertension management specifically to these deficits and thereby to improve control rates...
  61. ncbi Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage
    Heiko Funke-Kaiser
    Center for Cardiovascular Research Institute of Pharmacology, Charite University Medicine Berlin, Berlin, Germany
    Hypertens Res 33:98-104. 2010
    ..Finally, the rationale and strategy for the development of small-molecule antagonists of the (P)RR, called renin/prorenin receptor blockers, are presented...
  62. ncbi The metabolic syndrome: cluster with a self-fulfilling loop?
    Markus Clemenz
    Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Hypertens 24:257-8. 2006
  63. ncbi p38 MAP kinase negatively regulates angiotensin II-mediated effects on cell cycle molecules in human coronary smooth muscle cells
    Ulrich Kintscher
    Institute of Pharmacology and Toxicology, Charite Hospital, Humboldt University Berlin, D 10117 Berlin, Germany
    Biochem Biophys Res Commun 305:552-6. 2003
    ..These findings support an important role for p38 MAPK in modulating AngII-mediated VSMC hyperplasia...
  64. ncbi Contribution of bradykinin and nitric oxide to AT2 receptor-mediated differentiation in PC12 W cells
    Yi Zhao
    Institute of Pharmacology, Christian Albrechts University of Kiel, Kiel, Germany
    J Neurochem 85:759-67. 2003
    ..The effects of angiotensin II on cell differentiation and cyclic GMP production were mediated via the AT2 receptor and further enhanced by bradykinin B2 receptor blockade...
  65. ncbi Endothelial dysfunction and its role in diabetic vascular disease
    Martin M Hartge
    Center for Cardiovascular Research, Institute for Pharmacology, , Hessische Strasse 3-4, 10115 Berlin, Germany
    Endocrinol Metab Clin North Am 35:551-60, viii-ix. 2006
    ..Subsequently future therapeutic approaches for the treatment of diabetic cardiovascular disease should target the dysfunctional endothelium first...
  66. ncbi Mast cells and the power of local RAS activation
    Harm Peters
    Department of Nephrology, , Charit, Campus Mitte, Humboldt University, , D-10098 Berlin, Germany
    Nephrol Dial Transplant 22:40-2. 2007
  67. ncbi Advances in cardiovascular research. 15th Annual Meeting of the European Council for Cardiovascular Research (ECCR). La Colle sur Loup, France, 8–10 October 2010
    U Muscha Steckelings
    Center for Cardiovascular Research, Charite Universitatsmedizin Berlin, Hessische Str 3 4, 10115 Berlin, Germany
    Expert Rev Cardiovasc Ther 9:21-5. 2011
    ..This article summarizes highlights of the oral sessions, workshops and keynote lectures...
  68. ncbi Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats
    Wolf Groth
    Institute of Pharmacology, University Hospital of Schleswig-Holstein, Christian-Albrechts-University of Kiel, 24105 Kiel, Germany
    J Hypertens 21:2175-82. 2003
    ..CONCLUSION: Long-term blockade of AT1 receptors improves neurological outcome of focal cerebral ischaemia and protects brain tissue against ischaemic injury...
  69. ncbi Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma
    Anna Foryst-Ludwig
    Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
    PLoS Genet 4:e1000108. 2008
    ....
  70. ncbi The angiotensin AT2 receptor in inflammation
    Franziska Rompe
    Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Drug News Perspect 23:104-11. 2010
    ..Finally, it will give a brief outlook into new possibilities in AT(2) receptor research and in the potential utilization of AT(2) receptor stimulation as a novel pharmacological concept in anti-inflammation...
  71. ncbi Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives
    Thomas Unger
    Institute of Pharmacology and Toxicology, , Humboldt University at Berlin, Berlin, Germany
    Drug Saf 26:707-20. 2003
    ..The physician can help by prescribing agents with a low potential for interaction, such as angiotensin receptor blockers...
  72. ncbi Calcium channel blockade limits transcriptional, translational and functional up-regulation of the cardiac calpain system after myocardial infarction
    Steffen Sandmann
    Institute of Pharmacology, Christian Albrechts University of Kiel, Hospitalstrasse 4, 24105 Kiel, Germany
    Eur J Pharmacol 453:99-109. 2002
    ..Cardiac L- and T-type Ca(2+) channel blockade differentially reduced postinfarction remodeling associated with selective inhibition of cardiac calpains I and II, respectively...
  73. ncbi Identification of a zinc finger homoeodomain enhancer protein after AT(2) receptor stimulation by differential mRNA display
    Monika Stoll
    Department of Physiology, Medical College of Wisconsin, Milwaukee, USA
    Arterioscler Thromb Vasc Biol 22:231-7. 2002
    ..In conclusion, Zfhep not only represents a suitable marker for AT(2) receptor activation, but it may also link AT(2) signaling and downstream events involved in the proposed function of the AT(2) receptor in development and regeneration...
  74. ncbi [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure]
    Steffen Sandmann
    Institut de Pharmacologie et Toxicologie, Université de Berlin Charite Humboldt, Berlin, Allemagne
    Drugs 62:43-52. 2002
    ..These substances have been shown to decrease morbidity and mortality of patients with heart failure and renal disease associated with diabetes...
  75. ncbi Pathophysiologic and therapeutic importance of tissue ACE: a consensus report
    Victor J Dzau
    Department of Medicine, Brigham Women s Hospital, Boston, MA 02115, USA
    Cardiovasc Drugs Ther 16:149-60. 2002
    ..Pharmacologic studies show that while ACE inhibitors may differ according to their binding affinity for tissue ACE the clinical significance remains to be determined...
  76. ncbi Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism
    Dirk Westermann
    Department of Cardiology, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Diabetes 56:641-6. 2007
    ..These findings present evidence that AT-1 receptor antagonists attenuate cardiac failure by decreasing cardiac inflammation and normalizing MMP activity, leading to normalized cardiac fibrosis in STZ-induced diabetic cardiomyopathy...
  77. ncbi Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats
    Steffen Sandmann
    Center for Cardiovascular Research (CCR)/Institute of Pharmacology and Toxicology, , Germany
    Blood Press 15:116-28. 2006
    ....
  78. ncbi Angiotensin receptor blockers and cerebral protection in stroke
    Christa Thone-Reineke
    Centre for Cardiovascular Research Institute for Pharmacology and Toxicology, Charite Universitatsmedizin Berlin, Germany
    J Hypertens Suppl 24:S115-21. 2006
    ..ARBs have been proven to be effective in the prevention of stroke via mechanisms that are both dependent on and independent of the antihypertensive abilities of the drugs...
  79. ncbi Differential effect of acute angiotensin II type 1 receptor blockade on the vascular and adrenal response to exogenous angiotensin II in humans
    Katja Lottermoser
    , Bonn, Germany
    Am J Hypertens 16:445-52. 2003
    ..CONCLUSIONS: These results indicate that although the vascular response to exogenous angiotensin II is exclusively mediated by the AT(1) receptor, the effects of angiotensin II on adrenal aldosterone release may involve other pathways...
  80. ncbi Comparison of cardioprotective effects of mibefradil and ramipril in stroke-prone spontaneously hypertensive rats
    Qin gui Xia
    Department of Physiology, Wenzhou Medical College, Wenzhou 325027, China
    Acta Pharmacol Sin 25:763-8. 2004
    ....
  81. ncbi Angiotensin receptor blockers: therapeutic targets and cardiovascular protection
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octobre, Madrid, Spain, and Division of Internal Medicine, Ospedali Civili, University of Brescia, Italy
    Blood Press 14:196-209. 2005
    ..Furthermore, evidence in favour of combining an ACE inhibitor and an ARB in certain circumstances is continuously growing...
  82. ncbi Angiotensin II and the fibroproliferative response to acute lung injury
    Richard P Marshall
    Centre for Respiratory Research, Royal Free and University College London Medical School, Rayne Institute, UK
    Am J Physiol Lung Cell Mol Physiol 286:L156-64. 2004
    ..ACE inhibitors and receptor antagonists, already widely used clinically, should be assessed as potential new therapies for fibrotic lung disease...
  83. ncbi Does the AT2-receptor mediate anti-atherosclerotic actions?
    Ulrich Kintscher
    J Hypertens 23:1469-70. 2005
  84. ncbi Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury
    Jun Li
    Center for Cardiovascular Research/Institute of Pharmacology and Toxicology, , Germany
    FASEB J 19:617-9. 2005
    ..Our data indicate that cerebral AT2 receptors exert neuroprotective actions in response to ischemia-induced neuronal injury, possibly by supporting neuronal survival and neurite outgrowth in peri-ischemic brain areas...
  85. ncbi The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League
    Stephan Lüders
    Department of Internal Medicine, St Josefs Hospital, Cloppenburg, Germany
    J Hypertens 26:1487-96. 2008
    ....
  86. ncbi [Awards for research and development of acarbose]
    Thomas Unger

    Med Klin (Munich) 98:18-9. 2003
  87. ncbi Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled
    Peter Bramlage
    Institute of Clinical Pharmacology, Institute of Clinical Psychology and Psychotherapy, Technical University, Dresden
    Am J Hypertens 17:904-10. 2004
    ..The objective of this study was to assess the prevalence of hypertension and the diagnosis, treatment status, and control rates of hypertension in obese patients as compared to patients with normal weight...
  88. ncbi Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme
    Mathias Zimmermann
    Center for Cardiovascular Research/Institute for Pharmacology and Toxicology, , Germany
    Expert Opin Pharmacother 5:1201-8. 2004
    ..The secondary end points will focus on reductions in the development of Type 2 diabetes mellitus, nephropathy, cognitive decrease and dementia as well as atrial fibrillation...
  89. ncbi Effects of endothelin ETA receptor blocker LU 135252 on cardiac remodeling and survival in a hypertensive rat model of chronic heart failure
    Qin gui Xia
    Department of Physiology, Wenzhou Medical College, Wenzhou 325027, China
    Acta Pharmacol Sin 27:1417-22. 2006
    ..To investigate whether the endothelin ETA receptor blocker provides similar benefit on cardiac remodeling and survival in a hypertensive rat model of chronic heart failure (CHF)...